EGFR and breast carcinoma: In both BT474 and in SUM149 mammary carcinoma cells, expression of constitutively active STAT3; or of activated AKT; or of activated MEK1 were shown to be a key individual protective molecular signals to suppress (ruxolitinib + ERBB inhibitor) – induced killing, though of additional note molecular inhibition of JNK pathway signaling could also reduce the death response.